Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1210MR)

This product GTTS-WQ1210MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1210MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6322MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ13119MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ366MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ14345MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ10025MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ13846MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ13446MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ15166MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA T1h
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW